

Systemic Sclerosis (Scleroderma): Epidemiology Forecasting Intelligence

https://marketpublishers.com/r/S1E98630CFCEN.html

Date: February 2019

Pages: 50

Price: US\$ 2,500.00 (Single User License)

ID: S1E98630CFCEN

Abstracts

CmaxInsight's "Systemic Sclerosis (Scleroderma)-Epidemiology Forecasting Intelligence" report provides a comprehensive analysis of the Systemic Sclerosis (Scleroderma) epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.

Our epidemiology services include:

Incidence and prevalence

Diagnosis rate, treatment rate and mortality patterns

Epidemiology-based forecasting and disease trends

Size of different patient segments in a disease area

Population based: disease occurrence, co-morbidities and treatment patterns

Geographic - Regional - Ethnic differences

Along with the epidemiological data, the report also includes:

Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment



Patient treatment journey

Treatment algorithm and guidelines

Assesses the disease risk and burden

Highlights the unmet needs

Market driver and barrier

Growth opportunities and market trend analysis

Methodology

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.

To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.

All of the sources used to generate the data and analysis have been identified in the report.

Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods. This report can be delivered to the clients within 4-5 business days.



Contents

- 1. REPORT INTRODUCTION
- 2. SYSTEMIC SCLEROSIS (SCLERODERMA) EPIDEMIOLOGY OVERVIEW AT A GLANCE
- 3. MARKET SHARE DISTRIBUTION OF SYSTEMIC SCLEROSIS (SCLERODERMA)
- 4. DISEASE BACKGROUND AND OVERVIEW: SYSTEMIC SCLEROSIS (SCLERODERMA)
- 4.1. Introduction
- 4.2. Signs and Symptoms
- 4.3. Etiology
- 4.4. Risk Factors
- 4.5. Pathophysiology
- 4.6. Diagnostic Landscape
 - 4.6.1. Diagnostic Practices
 - 4.6.2. Diagnostic Criteria
 - 4.6.3. Diagnostic Recommendations
- 4.7. Treatment Landscape
 - 4.7.1. Current Treatment Practices
 - 4.7.2. Treatment Algorithm
 - 4.7.3. Treatment Recommendations
- 5. SYSTEMIC SCLEROSIS (SCLERODERMA) EPIDEMIOLOGY
- 5.1. Key Findings
- 5.2. Assumptions & Rationale
- 5.3. 7MM Epidemiology
- 6. EPIDEMIOLOGY OF SYSTEMIC SCLEROSIS (SCLERODERMA) BY COUNTRIES
- 7. UNITED STATES
- 7.1. Assumptions and Rationale
- 7.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
- 7.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*



- 7.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
- 7.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
- 7.6. Treated Cases of Systemic Sclerosis (Scleroderma)

8. EU5

- 8.1. Germany
 - 8.1.1. Assumptions and Rationale
 - 8.1.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
 - 8.1.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
 - 8.1.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
 - 8.1.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
 - 8.1.6. Treated Cases of Systemic Sclerosis (Scleroderma)
- 8.2. France
 - 8.2.1. Assumptions and Rationale
- 8.2.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
- 8.2.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
- 8.2.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
- 8.2.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
- 8.2.6. Treated Cases of Systemic Sclerosis (Scleroderma)
- 8.3. United Kingdom
 - 8.3.1. Assumptions and Rationale
 - 8.3.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
 - 8.3.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
 - 8.3.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
 - 8.3.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
 - 8.3.6. Treated Cases of Systemic Sclerosis (Scleroderma)
- 8.4. Spain
 - 8.4.1. Assumptions and Rationale
 - 8.4.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
 - 8.4.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
 - 8.4.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
 - 8.4.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
 - 8.4.6. Treated Cases of Systemic Sclerosis (Scleroderma)
- 8.5. Italy
 - 8.5.1. Assumptions and Rationale
 - 8.5.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
- 8.5.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
- 8.5.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*



- 8.5.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
- 8.5.6. Treated Cases of Systemic Sclerosis (Scleroderma)

9. JAPAN

- 9.1. Assumptions and Rationale
- 9.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
- 9.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
- 9.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
- 9.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
- 9.6. Treated Cases of Systemic Sclerosis (Scleroderma)

10. UNMET NEEDS

Appendix

Report Methodology

Sources Used

Disclaimer

About CmaxInsight

*Indication Specific

Note: Certain sections of the table of contents would vary according to the availability of information.



List Of Tables

LIST OF TABLES

- Table 1: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM
- Table 2: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM by Countries
- Table 3: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in United States
- Table 4: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in United States*
- Table 5: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in United States*
- Table 6: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in United States
- Table 7: Treated Cases of the Systemic Sclerosis (Scleroderma) in United States
- Table 8: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Germany
- Table 9: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany*
- Table 10: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany*
- Table 11: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Germany
- Table 12: Treated Cases of the Systemic Sclerosis (Scleroderma) in Germany
- Table 13: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in France
- Table 14: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in France*
- Table 15: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in France*
- Table 16: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in France
- Table 17: Treated Cases of the Systemic Sclerosis (Scleroderma) in France
- Table 18: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Italy
- Table 19: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy*
- Table 20: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy*
- Table 21: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Italy
- Table 22: Treated Cases of the Systemic Sclerosis (Scleroderma) in Italy
- Table 23: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Spain
- Table 24: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain*
- Table 25: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain*
- Table 26: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Spain
- Table 27: Treated Cases of the Systemic Sclerosis (Scleroderma) in Spain
- Table 28: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in UK
- Table 29: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in UK*
- Table 30: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in UK*



- Table 31: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in UK
- Table 32: Treated Cases of the Systemic Sclerosis (Scleroderma) in UK
- Table 33: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Japan
- Table 34: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan*
- Table 35: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan*
- Table 36: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Japan
- Table 37: Treated Cases of the Systemic Sclerosis (Scleroderma) in Japan

^{*}Indication Specific



List Of Figures

LIST OF FIGURES

- Figure 1: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM
- Figure 2: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM by Countries
- Figure 3: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in United States
- Figure 4: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in United States*
- Figure 5: Sex-Specific Cases of the Systemic Sclerosis (Scleroderma) in United States*
- Figure 6: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in United States
- Figure 7: Treated Cases of the Systemic Sclerosis (Scleroderma) in United States
- Figure 8: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Germany
- Figure 9: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany*
- Figure 10: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany*
- Figure 11: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Germany
- Figure 12: Treated Cases of the Systemic Sclerosis (Scleroderma) in Germany
- Figure 13: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in France
- Figure 14: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in France*
- Figure 15: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in France*
- Figure 16: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in France
- Figure 17: Treated Cases of the Systemic Sclerosis (Scleroderma) in United France
- Figure 18: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Italy
- Figure 19: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy*
- Figure 20: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy*
- Figure 21: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Italy
- Figure 22: Treated Cases of the Systemic Sclerosis (Scleroderma) in Italy
- Figure 23: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Spain
- Figure 24: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain*
- Figure 25: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain*
- Figure 26: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Spain
- Figure 27: Treated Cases of the Systemic Sclerosis (Scleroderma) in Spain
- Figure 28: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in UK
- Figure 29: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in UK*
- Figure 30: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in UK*



Figure 31: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in UK

Figure 32: Treated Cases of the Systemic Sclerosis (Scleroderma) in UK

Figure 33: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Japan

Figure 34: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan*

Figure 35: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan*

Figure 36: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Japan

Figure 37: Treated Cases of the Systemic Sclerosis (Scleroderma) in Japan

^{*}Indication Specific



I would like to order

Product name: Systemic Sclerosis (Scleroderma): Epidemiology Forecasting Intelligence

Product link: https://marketpublishers.com/r/S1E98630CFCEN.html

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/S1E98630CFCEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970